- About this Journal ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 420597, 8 pages
Endocytic Adaptor Protein Epsin Is Elevated in Prostate Cancer and Required for Cancer Progression
1Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
2Biochemistry and Molecular Biology Department, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
Received 7 February 2013; Accepted 27 February 2013
Academic Editors: Y. Akiyama, J. Bentel, Z. S. Guo, and Y. Yu
Copyright © 2013 Kandice L. Tessneer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Y. Jung, Y. Shiozawa, J. Wang et al., “Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment,” Neoplasia, vol. 14, no. 5, pp. 429–439, 2012.
- Y. Chen and H. I. Scher, “Prostate cancer in 2011: hitting old targets better and identifying new targets,” Nature Reviews Clinical Oncology, vol. 9, no. 2, pp. 70–72, 2012.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.
- Z. I. Khamis, K. A. Iczkowski, and Q. X. A. Sang, “Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents,” Medicinal Research Reviews, vol. 32, no. 5, pp. 1026–1077, 2011.
- S. Ramaswamy, K. N. Ross, E. S. Lander, and T. R. Golub, “A molecular signature of metastasis in primary solid tumors,” Nature Genetics, vol. 33, no. 1, pp. 49–54, 2003.
- Z. Wang, Y. Li, S. Banerjee et al., “Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-κB signaling pathways,” Journal of Cellular Biochemistry, vol. 109, no. 4, pp. 726–736, 2010.
- J. K. Oosterhoff, J. A. Grootegoed, and L. J. Blok, “Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling,” Endocrine-Related Cancer, vol. 12, no. 1, pp. 135–148, 2005.
- J. K. Oosterhoff, L. C. Kühne, J. A. Grootegoed, and L. J. Blok, “EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2,” International Journal of Cancer, vol. 113, no. 4, pp. 561–567, 2005.
- J. Wang, W. Yu, Y. Cai, C. Ren, and M. M. Ittmann, “Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression,” Neoplasia, vol. 10, no. 8, pp. 847–856, 2008.
- S. Gupta, K. Iljin, H. Sara et al., “FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells,” Cancer Research, vol. 70, no. 17, pp. 6735–6745, 2010.
- K. G. Bache, T. Slagsvold, and H. Stenmark, “Defective downregulation of receptor tyrosine kinases in cancer,” EMBO Journal, vol. 23, no. 14, pp. 2707–2712, 2004.
- H. Barriere, C. Nemes, D. Lechardeur, M. Khan-Mohammad, K. Fruh, and G. L. Lukacs, “Molecular basis of oligoubiquitin-dependent internalization of membrane proteins in mammalian cells,” Traffic, vol. 7, no. 3, pp. 282–297, 2006.
- H. Chen and P. De Camilli, “The association of epsin with ubiquitinated cargo along the endocytic pathway is negatively regulated by its interaction with clathrin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2766–2771, 2005.
- H. Chen, S. Fre, V. I. Slepnev et al., “Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis,” Nature, vol. 394, no. 6695, pp. 793–797, 1998.
- M. G. J. Ford, I. G. Mills, B. J. Peter et al., “Curvature of clathrin-coated pits driven by epsin,” Nature, vol. 419, no. 6905, pp. 361–366, 2002.
- M. J. Hawryluk, P. A. Keyel, S. K. Mishra, S. C. Watkins, J. E. Heuser, and L. M. Traub, “Epsin 1 is a polyubiquitin-selective clathrin-associated sorting protein,” Traffic, vol. 7, no. 3, pp. 262–281, 2006.
- J. A. Rosenthal, H. Chen, V. I. Slepnev et al., “The epsins define a family of proteins that interact with components of the clathrin coat and contain a new protein module,” Journal of Biological Chemistry, vol. 274, no. 48, pp. 33959–33965, 1999.
- S. C. Shih, D. J. Katzmann, J. D. Schnell, M. Sutanto, S. D. Emr, and L. Hicke, “Epsins and Vps27p/Hrs contain ubiquitin-binding domains that function in receptor endocytosis,” Nature Cell Biology, vol. 4, no. 5, pp. 389–393, 2002.
- S. Sugiyama, S. Kishida, K. Chayama, S. Koyama, and A. Kikuchi, “Ubiquitin-interacting motifs of epsin are involved in the regulation of insulin-dependent endocytosis,” Journal of Biochemistry, vol. 137, no. 3, pp. 355–364, 2005.
- B. Wendland, “Epsins: adaptors in endocytosis?” Nature Reviews Molecular Cell Biology, vol. 3, no. 12, pp. 971–977, 2002.
- G. Ko, S. Paradise, H. Chen et al., “Selective high-level expression of epsin 3 in gastric parietal cells, where it is localized at endocytic sites of apical canaliculi,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 50, pp. 21511–21516, 2010.
- H. Chen, G. Ko, A. Zatti et al., “Embryonic arrest at midgestation and disruption of Notch signaling produced by the absence of both epsin 1 and epsin 2 in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13838–13843, 2009.
- S. Pasula, X. Cai, Y. Dong et al., “Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling,” Journal of Clinical Investigation, vol. 122, no. 12, pp. 4424–4438, 2012.
- R. S. Kerbel, “Tumor angiogenesis,” New England Journal of Medicine, vol. 358, no. 19, pp. 2039–2049, 2008.
- B. G. Coon, J. Burgner, J. H. Camonis, and R. C. Aguilar, “The Epsin family of endocytic adaptors promotes fibrosarcoma migration and invasion,” Journal of Biological Chemistry, vol. 285, no. 43, pp. 33073–33081, 2010.
- B. G. Coon, D. M. DiRenzo, S. F. Konieczny, and R. C. Aguilar, “Epsins' novel role in cancer cell invasion,” Communicative & Integrative Biology, vol. 4, no. 1, pp. 95–97, 2011.
- D. Mukherjee, B. G. Coon, D. F. Edwards et al., “The yeast endocytic protein Epsin 2 functions in a cell-division signaling pathway,” Journal of Cell Science, vol. 122, no. 14, pp. 2453–2463, 2009.
- B. Tanos and E. Rodriguez-Boulan, “The epithelial polarity program: machineries involved and their hijacking by cancer,” Oncogene, vol. 27, no. 55, pp. 6939–6957, 2008.
- C. Rossé, S. L'Hoste, N. Offner, A. Picard, and J. Camonis, “RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate Epsin during the switch off of endocytosis in mitosis,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 30597–30604, 2003.
- R. C. Aguilar, S. A. Longhi, J. D. Shaw et al., “Epsin N-terminal homology domains perform an essential function regulating Cdc42 through binding Cdc42 GTPase-activating proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 11, pp. 4116–4121, 2006.
- N. M. Mollberg, G. Steinert, M. Aigner et al., “Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse,” Cancer Biology and Therapy, vol. 13, no. 8, pp. 695–701, 2012.
- J. S. Horoszewicz, S. S. Leong, and E. Kawinski, “LNCaP model of human prostatic carcinoma,” Cancer Research, vol. 43, no. 4, pp. 1809–1818, 1983.
- N. M. Greenberg, F. DeMayo, D. Medina et al., “Prostate cancer in a transgenic mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3439–3443, 1995.
- J. R. Gingrich, R. J. Barrios, M. W. Kattan, H. S. Nahm, M. J. Finegold, and N. M. Greenberg, “Androgen-independent prostate cancer progression in the TRAMP model,” Cancer Research, vol. 57, no. 21, pp. 4687–4691, 1997.
- J. R. Gingrich, R. J. Barrios, R. A. Morton et al., “Metastatic prostate cancer in a transgenic mouse,” Cancer Research, vol. 56, no. 18, pp. 4096–4102, 1996.
- J. R. Gingrich and N. M. Greenberg, “A transgenic mouse prostate cancer model,” Toxicologic Pathology, vol. 24, no. 4, pp. 502–504, 1996.
- G. N. Thalmann, P. E. Anezinis, S. M. Chang et al., “Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer,” Cancer Research, vol. 54, no. 10, pp. 2577–2581, 1994.
- H. C. Wu, J. T. Hsieh, M. E. Gleave, N. M. Brown, S. Pathak, and L. W. K. Chung, “Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells,” International Journal of Cancer, vol. 57, no. 3, pp. 406–412, 1994.
- J. R. Gingrich, R. J. Barrios, B. A. Foster, and N. M. Greenberg, “Pathologic progression of autochthonous prostate cancer in the TRAMP model,” Prostate Cancer and Prostatic Diseases, vol. 2, no. 2, pp. 70–75, 1999.